SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Juan Turnes, Roberto Díaz, Manuel Hernandez-Guerra, Mariano Gómez, Lluís Castells, Javier Bustamante, M. Dolores Espinosa, Javier Fernández-Castroagudín, Trinidad Serrano, Paloma Rendón, Raúl Andrade, Mercedes Salgado, Juan Arenas, Mercedes Vergara, Margarita Sala, Benjamín Arturo Polo, Ignacio Martín Granizo, María Luisa Gonzálvez, Antonio Viudez, Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España, Gastroenterología y Hepatología, 2015, 38, 4, 263

    CrossRef

  2. 2
    Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo, Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 2015, 61, 4
  3. 3
    Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Cammà, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo, Refining sorafenib therapy: lessons from clinical practice, Future Oncology, 2015, 11, 3, 449

    CrossRef

  4. 4
    Omar Abdel-Rahman, Mona Fouad, Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review, Expert Review of Anticancer Therapy, 2015, 15, 2, 165

    CrossRef

  5. 5
    Marcus-Alexander Wörns, Peter Robert Galle, HCC therapies—lessons learned, Nature Reviews Gastroenterology & Hepatology, 2014, 11, 7, 447

    CrossRef

  6. 6
    J. Bruix, G. J. Gores, V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, 2014, 63, 5, 844

    CrossRef

  7. 7
    Antonio Facciorusso, Valentina Del Prete, Matteo Antonino, Nicola Crucinio, Viviana Neve, Alfredo Di Leo, Brian I. Carr, Michele Barone, Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation, Digestive and Liver Disease, 2014, 46, 11, 1014

    CrossRef

  8. 8
    Alejandro Forner, Álvaro Díaz-González, Alexandre Liccioni, Ramón Vilana, Prognosis prediction and staging, Best Practice & Research Clinical Gastroenterology, 2014, 28, 5, 855

    CrossRef

  9. 9
    Won Sohn, Yong-Han Paik, Ju-Yeon Cho, Ho Yeong Lim, Jem Ma Ahn, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors, Journal of Hepatology, 2014,

    CrossRef

  10. 10
    Giulia Castelli, Patrizia Burra, Anna Giacomin, Alessandro Vitale, Marco Senzolo, Umberto Cillo, Fabio Farinati, Sorafenib use in the transplant setting, Liver Transplantation, 2014, 20, 9
  11. 11
    David Bolos, Richard S. Finn, Systemic therapy in HCC: Lessons from brivanib, Journal of Hepatology, 2014, 61, 4, 947

    CrossRef

  12. 12
    Maria Reig, Alessia Gazzola, Roberto Di Donato, Jordi Bruix, Systemic treatment, Best Practice & Research Clinical Gastroenterology, 2014, 28, 5, 921

    CrossRef

  13. 13
    Lorenza Rimassa, Camillo Porta, Ivan Borbath, Bruno Daniele, Richard S Finn, Jean-Luc Raoul, Lawrence H Schwartz, Aiwu Ruth He, Joerg Trojan, Markus Peck-Radosavljevic, Giovanni Abbadessa, Terri Goldberg, Armando Santoro, Jordi Bruix, Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial, Hepatic Oncology, 2014, 1, 2, 181

    CrossRef

  14. 14
    Alejandro Forner, Marine Gilabert, Jordi Bruix, Jean-Luc Raoul, Treatment of intermediate-stage hepatocellular carcinoma, Nature Reviews Clinical Oncology, 2014, 11, 9, 525

    CrossRef